Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Biovance 3L's unique tri-layer membrane construction is designed for improved handling and ease of use as a covering, barrier, or wrap to surgical sites. The three-dimensional design provides more surface area, allows for suturing as required, and serves as a cell-friendly structure that promotes cell attachment within hours.Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) Q code for Biovance 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds. The designated HCPCS Q code is Q4283 and is available starting April 1, 2024.
开发胎盘衍生异基因细胞疗法和先进生物材料产品的再生医学公司Celularity Inc.（纳斯达克股票代码：CELU）（“Celularity”）今天宣布，美国医疗保险和医疗补助服务中心（CMS）已授予Biovance 3L的医疗保健通用程序编码系统（HCPCS）Q码，这是一种源自胎盘组织的三层同种异体移植物用作覆盖屏障的生物膜或包裹，用作修复局部和全厚度、急性和慢性伤口功能组织的支架。指定的 HCPCS Q 代码为 Q4283，自 2024 年 4 月 1 日起上线。
"The HCPCS Q code approval by CMS further recognizes Biovance 3L as an important therapeutic option for the treatment of wounds," said Dr. Robert J. Hariri, M.D., Ph.D., Celularity CEO, chairman and founder. "The medical community has been rapidly adopting this product, and the HCPCS Q code approval paves the way for Biovance 3L to realize additional growth, enabling the potential to impact more lives. As one of our leading biomaterial products, we are excited about the potential impact this approval may have on Celularity's performance throughout the remainder of 2024 and beyond. We will continue to innovate in this important part of our business and look forward to providing future updates."
Celularity首席执行官、董事长兼创始人罗伯特·哈里里博士说：“CMS批准的HCPCSQ代码进一步认可Biovance 3L是治疗伤口的重要治疗选择。”“医学界一直在迅速采用该产品，HCPCS Q码批准为Biovance 3L实现额外增长铺平了道路，从而有可能影响更多生活。作为我们领先的生物材料产品之一，我们对该批准可能对Celularity在2024年剩余时间及以后的业绩产生的潜在影响感到兴奋。我们将继续在业务的这一重要部分进行创新，并期待提供未来的更新。”
The Healthcare Common Procedure Coding System (HCPCS) is produced by the Centers for Medicare and Medicaid Services (CMS). HCPCS is a group of standardized codes that represent medical procedures, supplies, products, and services. The codes are used to facilitate the processing of health insurance claims by Medicare and other insurers. The Q codes are established to identify drugs, biologicals, and medical equipment or services not identified by national HCPCS Level II codes but for which codes are needed for Medicare claims processing. HCPCS code modifiers are established internally by CMS to facilitate accurate Medicare claims processing.
医疗保健通用程序编码系统（HCPCS）由医疗保险和医疗补助服务中心（CMS）制定。HCPCS 是一组代表医疗程序、用品、产品和服务的标准化代码。这些守则用于促进医疗保险和其他保险公司处理健康保险索赔。Q代码的建立是为了识别药物、生物制剂和医疗设备或服务，这些药物、生物制品和医疗设备或服务未被国家HCPCS二级代码识别，但医疗保险索赔处理需要哪些代码。HCPCS 代码修改器由 CMS 内部建立，旨在促进准确的医疗保险索赔处理。
Biovance 3L's unique tri-layer membrane construction is designed for improved handling and ease of use as a covering, barrier, or wrap to surgical sites. The three-dimensional design provides more surface area, allows for suturing as required, and serves as a cell-friendly structure that promotes cell attachment within hours.
Biovance 3L 独特的三层膜结构旨在改善操作性并易于使用，可用作手术部位的覆盖物、屏障或包裹。三维设计可提供更大的表面积，允许根据需要进行缝合，并且是一种细胞友好结构，可在数小时内促进细胞附着。